{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:01:06Z","timestamp":1771556466013,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T00:00:00Z","timestamp":1549756800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/jac\/dkz010","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T03:09:51Z","timestamp":1547003391000},"page":"1300-1305","source":"Crossref","is-referenced-by-count":18,"title":["In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci"],"prefix":"10.1093","volume":"74","author":[{"given":"T","family":"Wu","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Meyer","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A T","family":"Harrington","sequence":"additional","affiliation":[{"name":"Loyola University Medical Center, Maywood, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L H","family":"Danziger","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"},{"name":"College of Medicine, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-8400","authenticated-orcid":false,"given":"E","family":"Wenzler","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"2019042309333017500_dkz010-B1","first-page":"217","article-title":"Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management","volume":"8","author":"O'Driscoll","year":"2015","journal-title":"Infect Drug Resist"},{"key":"2019042309333017500_dkz010-B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijantimicag.2014.08.002","article-title":"Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci","volume":"44","author":"Munita","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309333017500_dkz010-B3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/cid\/ciu642","article-title":"Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions","volume":"59","author":"Munita","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019042309333017500_dkz010-B4","year":"2018"},{"key":"2019042309333017500_dkz010-B5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/phar.1922","article-title":"Role of combination antimicrobial therapy for vancomycin-resistant Enterococcus faecium infections: review of the current evidence","volume":"37","author":"Yim","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2019042309333017500_dkz010-B6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jac\/dkv007","article-title":"\u03b2\u2013Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium","volume":"70","author":"Smith","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333017500_dkz010-B7","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1093\/infdis\/124.Supplement_1.S207","article-title":"Synergy of penicillin and gentamicin against enterococci","volume":"124","author":"Moellering","year":"1971","journal-title":"J Infect Dis"},{"key":"2019042309333017500_dkz010-B8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1128\/AAC.35.1.92","article-title":"Effects of combinations of \u03b2-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci","volume":"35","author":"Leclercq","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jgar.2014.09.004","article-title":"Assessment of the in vitro synergy of daptomycin plus linezolid against multidrug-resistant enterococci","volume":"2","author":"Entenza","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"2019042309333017500_dkz010-B10","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1128\/AAC.49.12.5166-5168.2005","article-title":"In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin","volume":"49","author":"Pankey","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B11","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1128\/AAC.36.12.2611","article-title":"Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium","volume":"36","author":"Caron","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B12","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1128\/AAC.05077-14","article-title":"In vitro activity of daptomycin in combination with \u03b2-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci","volume":"59","author":"Hindler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B13","first-page":"61","article-title":"In vitro synergy of telavancin and rifampin against Enterococcus faecium resistant to both linezolid and vancomycin","volume":"13","author":"Pankey","year":"2013","journal-title":"Ochsner J"},{"key":"2019042309333017500_dkz010-B14","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","article-title":"Oritavancin combinations with \u03b2-lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B15","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Seventh Edition: M100","year":"2017"},{"key":"2019042309333017500_dkz010-B16","doi-asserted-by":"crossref","first-page":"e02001","DOI":"10.1128\/JCM.02001-17","article-title":"Evaluation of non-tissue culture- versus tissue culture-treated microplates for oritavancin susceptibility testing","volume":"56","author":"Yan","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2019042309333017500_dkz010-B17","volume-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A","year":"1999"},{"key":"2019042309333017500_dkz010-B18","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1128\/AAC.00361-08","article-title":"Assessment by time\u2013kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus","volume":"52","author":"Belley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijantimicag.2015.08.014","article-title":"In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011\u20132014","volume":"46","author":"Biedenbach","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309333017500_dkz010-B20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive Gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2019042309333017500_dkz010-B21","doi-asserted-by":"crossref","first-page":"ofv156.","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2019042309333017500_dkz010-B22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.41.6.1293","article-title":"In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus","volume":"41","author":"Bahl","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B23","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.36.10.2201","article-title":"Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci","volume":"36","author":"Cercenado","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333017500_dkz010-B24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1128\/AAC.41.6.1307","article-title":"Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium","volume":"41","author":"Mercier","year":"1997","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/5\/1300\/28501279\/dkz010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T22:52:25Z","timestamp":1662763945000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/5\/1300\/5310330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,8]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz010","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,2,8]]}}}